IDEXX Laboratories Inc (IDXX)vsIQVIA Holdings Inc (IQV)
IDXX
IDEXX Laboratories Inc
$672.04
+0.06%
HEALTHCARE · Cap: $44.35B
IQV
IQVIA Holdings Inc
$258.44
-3.33%
HEALTHCARE · Cap: $45.35B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 280% more annual revenue ($17.31B vs $4.55B). IDXX leads profitability with a 25.0% profit margin vs 8.1%. IQV appears more attractively valued with a PEG of 0.98. IDXX earns a higher WallStSmart Score of 61/100 (C+).
IDXX
Buy61
out of 100
Grade: C+
IQV
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.6%
Fair Value
$436.51
Current Price
$672.04
$235.53 premium
Margin of Safety
+13.7%
Fair Value
$205.31
Current Price
$258.44
$53.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 71 in profit
Strong operational efficiency at 35.0%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 32.9x book value
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.
Bear Case : IDXX
The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, Altman Z-Score. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
IDXX profiles as a mature stock while IQV is a value play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.55 — expect wider price swings.
IDXX is growing revenue faster at 9.7% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (61/100 vs 59/100), backed by strong 25.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?